Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 2/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL28299317 | 0.98 | CA1 (0.48) | CA1CA2CA9CA7CA12 | |
| SCHEMBL15092785 | 0.82 | SCD (0.40) | CA1CA2CA9CA7CA12 | |
| SCHEMBL13650681 | 0.81 | CA1 (0.47) | CA1CA2CA9CA7TP53 | |
| SCHEMBL16748959 | 0.80 | CA1 (0.58) | CA1CA2CA9CA7CA12 | |
| SCHEMBL28797040 | 0.78 | CA1 (0.38) | CA1CA2CA9TP53CA5A | |
| SCHEMBL26628331 | 0.78 | KDM4E (0.43) | CA1CA2CA9CA7CA12 | |
| SCHEMBL13637585 | 0.77 | NQO1 (0.56) | SMN1; SMN2TSHRTDP1PTGS2ALDH1A1 | |
| SCHEMBL13627721 | 0.77 | CA1 (0.40) | CA1CA2CA9TP53CA5A | |
| SCHEMBL14381288 | 0.75 | CYP2C9 (0.51) | CA1CA2CA9CA7CA12 | |
| SCHEMBL15684335 | 0.75 | CYP2C9 (0.51) | CA1CA2CA9CA7CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111454296-B | Palladium complex containing meta-carborane triazole ligand and preparation method and application thereof | 上海应用技术大学 | 2023-04-28 | — | — | CN | claimed |
| CN-111732613-A | Ferric iron complex containing meta-carborane ligand and preparation method and application thereof | 上海应用技术大学 | 2020-10-02 | — | — | CN | claimed |
| CN-111454296-A | Palladium complex containing m-carborane triazole ligand and preparation method and application thereof | 上海应用技术大学 | 2020-07-28 | — | — | CN | claimed |
| CN-111454298-A | Nickel complex containing m-carborane triazole ligand and preparation method and application thereof | 上海应用技术大学 | 2020-07-28 | — | — | CN | claimed |
| US-12473263-B2 | Bicyclic inhibitors of CBX chromodomains | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-11-18 | — | — | US | disclosed |
| US-12384763-B2 | Protein and/or peptide modification molecule | OSAKA UNIVERSITY (JP) | 2025-08-12 | — | — | US | disclosed |
| CN-116082253-B | 1-N-substituted 1,2, 3-triazole-4-carboxamide derivative and preparation method thereof | 浙大城市学院 | 2025-04-25 | — | — | CN | disclosed |
| WO-2025048243-A1 | NOVEL ISOXAZOLE COMPOUND AS TM4SF5-SPECIFIC INHIBITOR AND USE THEREOF | 서울대학교산학협력단 | 2025-03-06 | — | — | WO | disclosed |
| WO-2024086767-A2 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | GANNA BIO, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| CN-117624166-A | Triazole derivative and preparation method and application thereof | 苏州朗睿生物医药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-116947770-A | Method for synthesizing 4-cyano-1, 2, 3-triazole compound through 2, 2-trifluoroethyl ketone | 平顶山学院 | 2023-10-27 | — | — | CN | disclosed |
| EP-3875151-B1 | ALPHA-METHYL-SUBSTITUTED DIAZABICYCLO [4.3.1] DECANE DERIVATES FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2023-09-20 | — | — | EP | disclosed |
| US-20090269555-A1 | SURFACE NANOPATTERNING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009110007-A1 | SPIRO DERIVATIVES OF PARTHENIN AS NOVEL ANTICANCER AGENTS | COUNCIL QF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009105746-A2 | TRIAZOLES AND PROCESSES FOR PRODUCING THE SAME | UNIVERSITY OF SOUTH FLORIDA (US) | 2009-08-27 | — | — | WO | disclosed |
| US-7524408-B2 | photoreduction of an azide, photodecarbozylation of a carboxylic acid, photodenitrogenation and Wolff rearrangement of a diazoketone, and the photoreduction of an aromatic nitrocompound; charged nanoparticle from CdS and CdSe compounds as path-directable nanoparticle; | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-28 | — | — | US | disclosed |
| US-7186738-B2 | Antibacterial oxalidinones | ASTRAZENECA AB (SE) | 2007-03-06 | — | — | US | disclosed |
| US-20060079695-A1 | antibiotics such as (5R)-3-[3-Fluoro-4-(3-methylisoxazol-5-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one, having effective activity against both grampositive and gramnegative pathogens | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | US | disclosed |
| EP-1603903-A1 | ANTIBACTERIAL OXALIDINONES | AstraZeneca AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004083206-A1 | ANTIBACTERIAL OXALIDINONES | ASTRAZENECA AB (SE) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473263-B2 | Bicyclic inhibitors of CBX chromodomains | CBX2, CBX3, CBX6 | CA1 482/4885CA2 494/4885CA9 1023/4885 |
| US-20060079695-A1 | antibiotics such as (5R)-3-[3-Fluoro-4-(3-methylisoxazol-5-yl)phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-1,3-oxazolidin-2-one, having effective activity against both grampositive and gramnegative pathogens | HRH1, HRH2, HDHD5 | CA1 1620/4885CA2 2814/4885CA9 746/4885 |
| US-12384763-B2 | Protein and/or peptide modification molecule | PTMS, DNPEP, NPPA | CA1 342/4885CA2 1864/4885CA9 2126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.